Lack of effect of mild or moderate hepatic impairment on the pharmacokinetics of rimonabant.

被引：0
|
作者：
Grandison, Monica K. [1 ]
Kanamaluru, Vanaja [1 ]
Bishai, Raafat [1 ]
Lockwood, Graham [1 ]
Newton, John [1 ]
机构：
[1] Sanofi Aventis, Malvern, PA USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2007年 / 47卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
74
引用
收藏
页码：1199 / 1199
页数：1
相关论文
共 50 条
  • [11] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    David Schnell
    Susanne Buschke
    Holger Fuchs
    Dietmar Gansser
    Rainer-Georg Goeldner
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Sven Wind
    Marc Petersen-Sylla
    Atef Halabi
    Rüdiger Koenen
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 267 - 275
  • [12] Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment
    Wang, Jing
    Wang, Xiaodong
    Zhang, Zhi-Yi
    Arora, Sujata
    Lu, Sharon
    Kansra, Vikram
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (05): : 686 - 693
  • [13] Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
    Michael A. Tortorici
    Melvin Toh
    S. V. Rahavendran
    Robert R. LaBadie
    Christine W. Alvey
    Thomas Marbury
    Ernesto Fuentes
    Matthew Green
    Grace Ni
    Brian Hee
    Yazdi K. Pithavala
    Investigational New Drugs, 2011, 29 : 1370 - 1380
  • [14] Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment
    Zimmerman, JJ
    Lasseter, KC
    Lim, HK
    Harper, D
    Dilzer, SC
    Parker, V
    Matschke, K
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12): : 1368 - 1372
  • [15] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    DRUGS IN R&D, 2021, 21 (04) : 375 - 384
  • [16] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Charles E. Frost
    Van Ly
    Samira M. Garonzik
    Drugs in R&D, 2021, 21 : 375 - 384
  • [17] Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
    Desai, Amit
    Schmitt-Hoffmann, Anne-Hortense
    Mujais, Salim
    Townsend, Robert
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 3025 - 3031
  • [18] FTY720 pharmacokinetics in mild to moderate hepatic impairment
    Kovarik, JM
    Schmouder, RL
    Wang, SY
    Wiegand, H
    Dilzer, SC
    Lasseter, KC
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (04): : 446 - 452
  • [19] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    Critical Care, 12 (Suppl 2):
  • [20] Mild to Moderate Hepatic Impairment Has No Effect on the Single Dose Pharmacokinetics of Alisporivir (ALV)
    Kovacs, Steven J.
    Ke, June
    Praestgaard, Jens
    Barve, Avantika
    Zhang, Jie
    Maietta, Robert
    Sunkara, Gangadhar
    Stein, Daniel S.
    GASTROENTEROLOGY, 2013, 144 (05) : S977 - S977
12345